Polish pharmaceutical industry leaders express concerns over the increasing reliance on Chinese-produced active pharmaceutical ingredients (APIs), warning it poses a significant threat to the security of medication supplies in Europe.
In a recent conversation, Grzegorz Rychwalski, the Vice President of the Polish Association of Pharmaceutical Employers 'Domestic Drug Producers', highlighted that the majority of innovative drugs may soon be produced by Chinese companies. The increasing influx of Chinese drugs into Europe raises alarms among Polish manufacturers, who are seeking government support to bolster local production.
Rychwalski pointed out that the pharmaceutical sector in Poland is heavily reliant on active pharmaceutical ingredients (APIs) sourced predominantly from China and India, with over 80% of these ingredients being imported. This dependence creates a precarious situation for the pharmaceutical security of both Poland and the wider European Union, as any disruption in the supply chain could lead to critical shortages of essential medications.
As legislative processes continue regarding a bill to renew wholesale drug licensing and reimbursement policies, there is an urgent call for action to mitigate the risks posed by this dependency. Industry representatives stress that a minor interruption in supplies could result in significant gaps in the availability of crucial pharmaceuticals, threatening public health and safety across EU nations.
